Paraneoplastic syndromes …

Neuro-Oncology

Updated 10.15.2024
Released 03.16.1998
Expires For CME 10.15.2027

Paraneoplastic syndromes

Authors: Nicholas Butowski MD, Anh Huan Vo MD

See Contributor Disclosures

Editor: Rimas V Lukas MD

Paraneoplastic syndromes

In This Article

Quick Link

Introduction

Overview

Paraneoplastic neurologic syndromes can affect any part of the central or peripheral nervous system. These disorders are uncommon compared to other neurologic complications of systemic cancer, but affected patients often have severe and irreversible neurologic morbidity. Many patients have one or more of an ever-growing list of antineuronal or “onconeural” autoantibodies. Because most paraneoplastic syndromes are the presenting feature of the associated neoplasm, neurologists must be able to recognize and diagnose these syndromes promptly. In this article, the author provides an overview of clinical features, autoimmune aspects, and management of patients with known or suspected paraneoplastic disorders.

Key points

	• Neurologic paraneoplastic disorders are relatively rare but often disabling complications of a variety of systemic neoplasms.
	• Most, if not all, paraneoplastic disorders are believed to be caused by an autoimmune reaction against shared "onconeural" antigens, though the exact pathogenesis of most syndromes remains unclear.
	• Paraneoplastic disorders may present as any of a wide variety of clinical syndromes and are often a diagnostic challenge.
	• Prompt diagnosis and treatment of paraneoplastic disorders increases the likelihood of a more favorable neurologic outcome.

Historical note and terminology

The term "paraneoplastic" was originally applied to any disorder associated with neoplasia but not caused by direct tumor invasion or metastasis. In current usage, neurologic paraneoplastic disorders refer to nonmetastatic disorders that are not attributable to toxicity of cancer therapy, cerebrovascular disease, coagulopathy, infection, or toxic and metabolic causes.

Classic publications in the 1950s and 1960s delineated the clinical and pathologic features of several neurologic paraneoplastic syndromes (15; 04; 25; 08). Paraneoplastic disorders are far less common than nervous system metastases and are relatively rare compared to other nonmetastatic neurologic complications of systemic cancer, but they are worthy of consideration for several reasons:

	(1) In most patients with paraneoplastic disorders, the neurologic symptoms are the presenting feature of an otherwise undiagnosed tumor, and patients see a neurologist first. It is the neurologist's task to identify the disorder as paraneoplastic and to initiate the appropriate search for the tumor.
	(2) Among patients with a known cancer diagnosis, the paraneoplastic syndromes are an important part of the differential diagnosis of neurologic dysfunction.
	(3) Paraneoplastic disorders often cause severe and permanent neurologic morbidity.
	(4) Prompt recognition of a paraneoplastic disorder maximizes the likelihood of successful tumor treatment and a favorable neurologic outcome.

An international panel of experts published an updated set of criteria for diagnosing "definite," “probable,” or "possible" paraneoplastic neurologic disorders based on the phenotypes, presence of “high risk” or “intermediate risk” antibodies, and tumor association (22).

Clinical manifestations

Presentation and course

Paraneoplastic disorders can affect any part of the central or peripheral nervous system (21; 19). Many patients can be grouped into a recognizable clinical syndrome predominantly affecting one anatomic location or system (Table 1), such as limbic encephalitis or rapidly progressive cerebellar syndrome. Other patients do not neatly fit into this scheme as they have signs and symptoms of multiple anatomic locations, such as encephalomyelitis.

Table 1. Neurologic Paraneoplastic Disorders

Central nervous system	Peripheral nervous system
Multifocal encephalomyelitis Rapidly progressive cerebellar syndrome Limbic encephalitis Opsoclonus-myoclonus Extrapyramidal syndrome Brainstem encephalitis Myelitis Motor neuron disease Stiff-person syndrome Epilepsy Optic neuritis Retinal degeneration Doege-Potter syndrome	Sensory neuronopathy Nerve vasculitis Sensorimotor polyneuropathy Motor neuropathy Neuromyotonia Autonomic insufficiency Lambert-Eaton syndrome Myasthenia gravis Polymyositis/dermatomyositis Necrotizing myopathy Gastrointestinal pseudo-obstruction

Prognosis and complications

The neurologic outcome of patients with paraneoplastic syndromes varies considerably among different disorders. Some patients have major neurologic improvement solely with treatment of the associated neoplasm; this possibility places an obvious premium on prompt recognition of the paraneoplastic syndrome. Unfortunately, many patients are left with severe and permanent neurologic disability despite remission of the associated tumor. The success of tumor therapy or immunotherapy spans a spectrum: patients with Lambert-Eaton myasthenic syndrome generally have a gratifying response (45), whereas the great majority of patients with paraneoplastic encephalomyelitis or rapidly progressive cerebellar syndrome are left with severe permanent neurologic disability despite aggressive treatment. The outcome for patients with paraneoplastic opsoclonus, limbic encephalopathy, or stiff-person syndrome usually lies somewhere between these extremes.

Clinical vignette

A 34-year-old woman presented with several weeks of worsening cognitive problems, unusual behaviors, and hallucinations, culminating in catatonia. Although her EEG and MRI of the brain with contrast showed no overt abnormalities, her cerebrospinal fluid analysis detected lymphocytic pleocytosis (11 cells), normal protein, and glucose. Her clinical picture was concerning, specifically for autoimmune encephalitis due to anti-NDMAR antibodies, and the search for an underlying tumor revealed a small ovarian teratoma. Intravenous steroids and plasma exchange were administered, and the tumor was excised. Serum autoimmune encephalitis panel was negative, but cerebrospinal fluid autoimmune encephalitis panel showed anti-NMDAR antibody positivity. The patient improved over the next several weeks. She subsequently received two infusions of anti-CD20 monoclonal antibody rituximab to decrease the risk of relapses. Over the next 6 months, she returned to her baseline functional level, with only mild neurocognitive sequelae detectable on neuropsychological testing.

Biological basis

Etiology and pathogenesis

Most neurologic paraneoplastic disorders are believed to be autoimmune diseases, although, with some exceptions, the exact immunopathogenic mechanisms remain complex and unclear. For some paraneoplastic disorders, it is postulated that tumor cells express “high-risk” antigens, which are identical or antigenically related to molecules whose expression is normally restricted to neurons. The presence of these antibodies should prompt a thorough search for underlying malignancy. In rare instances, an autoimmune response initially arising against the tumor antigens “spills over” to attack neurons expressing the same or related antigens, leading to clinical neurologic disease. There are also “intermediate-risk” and “lower-risk” antibodies that are not as strongly related to underlying cancer. However, cancer screening should still be performed based on clinical suspicion. Aside from cancer, previous viral infection infections, such as HSV, have been linked to autoimmune encephalitis in pediatric patients (01).

Since the mid-1980s, there has been a steadily growing list of antineuronal antibodies identified in the sera of patients with paraneoplastic disorders (Table 2) (37; 12; 29; 22). Some paraneoplastic antibodies have selective neuronal reactivity and are found only in patients with a particular “clinical syndrome.” Examples include antirecoverin antibodies in patients with retinal degeneration and anti-Yo (PCA1) or anti-Tr antibodies in patients with rapidly progressive cerebellar syndrome. Most paraneoplastic autoantibodies show a more widespread or pan-neuronal reactivity and are associated with a variety of clinical neurologic syndromes or with multifocal encephalomyelitis (eg, anti-Hu [ANNA1] and anti-CV2 [CRMP5]). Patients (most frequently in the setting of small cell lung cancer) may have more than one type of autoantibody (27). The high degree of specificity of an autoantibody for a particular neurologic syndrome does not in itself prove that the antibodies are pathogenic.

The neuronal molecular targets of most autoantibodies have been characterized. Many of the initially discovered onconeural antibodies (eg, anti-Hu and anti-Yo) react with intracellular neuronal protein antigens (12; 29). Many of the protein antigens reacting with antineuronal antibodies are known to be expressed by the tumors from affected patients, providing circumstantial evidence supporting the general theory of an autoimmune response arising against shared "onconeural" antigens. Autoantibodies against cell-surface and synaptic proteins (eg, NMDA receptor, LGI1, etc.) have also been identified (10). Although they are not as strongly linked to underlying cancer, they exhibit a more favorable response to immunotherapy (03).

The proven or postulated immunopathogenic mechanisms for neurologic paraneoplastic disorders fall into four main categories:

(1) Autoantibodies against shared onconeural antigens directly cause neurologic disease. Of note, antibodies targeting intracellular antigens are more frequently linked to underlying cancer than those directed against cell surface antigens. Examples of both cell-surface and intracellular antibodies are listed below. For example:

	• Lambert-Eaton myasthenic syndrome is caused by antibodies that bind to and downregulate voltage-gated calcium channels at the presynaptic neuromuscular junction, leading to a reduction in the quantal release of acetylcholine by a nerve impulse.
	• Antibodies against the Caspr2 protein associated with voltage-gated potassium channels in patients with neuromyotonia are believed to cause prolonged motor neuron depolarization, leading to abnormal spontaneous muscle activity.
	• Antibodies against synaptic receptors or trans-synaptic protein complexes (eg, NMDA receptors, glutamate receptors, GABAB receptors, or the LGI1 protein) may cause neuronal injury or dysfunction in patients with limbic encephalitis (28; 31; 32; 26; 38).
	• Antibodies against voltage-gated calcium channels or glutamate receptors may directly mediate Purkinje cell injury in some patients with rapidly progressive cerebellar syndrome (33).
	• Antiamphiphysin antibodies may directly contribute to causing paraneoplastic stiff-person syndrome by blocking presynaptic GABAergic inhibition (18).
	• Anti-recoverin antibodies probably exert a direct cytotoxic effect in patients with paraneoplastic retinal degeneration, perhaps in concert with cellular immune effectors.

(2) A cellular immune reaction against onconeural antigens is the main cause of neuronal injury. This is probably true for most patients with rapidly progressive cerebellar syndrome, for patients with multifocal encephalomyelitis or sensory neuronopathy associated with small-cell lung cancer, and for at least some patients with paraneoplastic limbic encephalitis or opsoclonus-myoclonus. For these disorders, it is postulated that onconeural antigens released by apoptotic tumor cells are presented to T lymphocytes in draining peripheral lymph nodes, initiating a Th1 helper response that eventually gains access to the CNS and attacks neurons expressing the antigens. Evidence to support cell-mediated neuronal injury includes the presence of cytotoxic T lymphocytes in apposition to neurons in some patients (37; 02). Patients may also develop antineuronal antibodies (eg, anti-Yo, anti-Hu, and anti-Ma2). In vitro evidence suggests that anti-Hu and anti-Yo antibodies can exert a direct cytotoxic effect on neurons, but this effect is believed to be less important than that of cellular immune effectors in causing clinical disease. No fully successful animal models have reproduced cell-mediated paraneoplastic disorders in the CNS.

(3) Neoplastic plasma cells produce monoclonal paraproteins (immunoglobulins), which react with peripheral nerve antigens and cause neuropathy, eg, sensorimotor neuropathy associated with antimyelin-associated glycoprotein (anti-MAG) antibodies or sensory ataxic neuropathy associated with antidisialosyl ganglioside antibodies.

(4) Disorders that arise from other or poorly understood immune mechanisms, such as paraneoplastic necrotizing myelopathy, vasculitic neuropathy, and neuropathy associated with osteosclerotic myeloma and POEMS syndrome (42).

Table 2. Paraneoplastic Disorders and Autoantibodies

Clinical syndrome	Associated tumors	Autoantibodies*
Multifocal encephalomyelitis	SCLC, thymoma, testicular seminoma, others	anti-Hu, anti-CV2, anti-LGI1, anti-Ma1, anti-amphiphysin, anti-Ri (ANNA2), ANNA-3, Kelch-like protein (KLHL11)
Limbic encephalitis	SCLC	anti-Hu, anti-CV2, PCA-2, ANNA-3, anti-amphiphysin, anti- LGI1, anti-VGCC, anti-Zic4, anti-mGluR5, anti-GABABR, anti-AMPAR, anti-GAD, anti-Ri, anti-GFAP
	Testicular, breast	anti-Ma2, anti-mGluR1/2
	Thymoma	anti- LGI1, anti-CV2, anti-mGluR5, anti-AMPAR
	Hodgkin lymphoma	anti-mGluR5
	Ovarian teratoma, testicular	anti-NMDAR
Rapidly progressive cerebellar syndrome	Breast, ovarian, testicular seminoma, others	anti-Yo, anti-Ma1, anti-Ri, Kelch-like protein (KLHL11)
	SCLC, others	anti-Hu, anti-CV2, PCA-2, ANNA-3, antiamphiphysin, anti-VGCC, anti-Ri, anti-Zic4, anti-GAD, anti-GABABR, anti-PKC
	Lymphoma, others	anti-Tr, anti-mGluR1
Opsoclonus-myoclonus	Breast, ovarian	anti-Ri, anti-Yo, antiamphiphysin
	SCLC	anti-Hu, anti-Ri, anti-CV2, antiamphiphysin, anti-VGCC
	Neuroblastoma	anti-Hu, others
	Testicular, others	anti-Ma2, anti-Ma1, anti-CV2
Extrapyramidal syndrome	SCLC, thymoma, testicular	anti-CV2, anti-Hu, anti-LGI1, anti-Ma2
Brainstem encephalitis	SCLC, breast, others	anti-Hu, anti-Ri, anti-GABABR, anti-IGLON5
	Testicular	anti-Ma2, anti-KLHL11
Optic neuritis	SCLC, lymphoma, others	anti-CV2, anti-AQP4
Retinal degeneration	SCLC, others	antirecoverin, others
	Melanoma	antibipolar cell
Myelopathy	SCLC, thymoma, breast, others	anti-CV2, anti-amphiphysin, anti-AQP4, anti-GlyR, anti-GFAP
Stiff-person syndrome	Breast, SCLC, thymoma, others	antiamphiphysin, anti-Ri, anti-GAD, anti-GlyR
Motor neuron disease	SCLC, others	anti-Hu, anti-Ri
Sensory neuronopathy	SCLC, others	anti-Hu, anti-CV2, ANNA-3, anti-Ma1, antiamphiphysin
	Plasma cell dyscrasias	antidisialosyl gangliosides
Neuromyotonia	Thymoma, SCLC, others	anti-Caspr2
Sensorimotor polyneuropathy	SCLC, others	anti-Hu, anti-CV2, ANNA-3
	Plasma cell dyscrasias	anti-MAG
Autonomic insufficiency	SCLC, thymoma	anti-Hu, anti-ganglionic AchR, anti-Caspr2
Lambert-Eaton syndrome	SCLC	anti-VGCC, SOX-1
Myasthenia gravis	Thymoma	anti-AchR, antistriated muscle, anti-MUSK, anti-TIF-1y
This table lists only the most frequent associations. For each of the clinical syndromes, a number of other tumor types may be associated. A varying proportion of patients with each of the syndromes is "antibody-negative" or has one or more “atypical” autoantibody specificities that do not fit the well-characterized patterns listed. *At least some antibodies previously thought to bind to voltage-gated potassium channels have been shown to bind to one or more proteins closely associated with potassium channels in the central and peripheral nervous systems. These proteins include leucine-rich, glioma-inactivated protein 1 (LGI1) and contractin-associated protein-2 (Caspr2) (28). Abbreviations: AchR: acetylcholine receptor; AMPAR: amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor; AQP: aquaporin; Caspr2: contractin-associated protein-2; GABABR: GABAB receptor; GAD: glutamic acid decarboxylase; mGluR: metabotropic glutamate receptor; GlyR: glycine receptor; IGLON5: immunoglobulin-like cell adhesion molecule 5; KLH11: Kelch-like protein; LGI1: leucine-rich glioma-inactivated protein 1; MAG: myelin-associated glycoprotein; NMDAR: N-methyl-D-aspartate receptor; PKC: protein kinase-C; VGCC: voltage-gated calcium channel

Differential diagnosis

Confusing conditions

Differential diagnosis in a patient with a suspected paraneoplastic disorder varies, depending on whether cancer is a known diagnosis. Among patients with neurologic dysfunction and a known cancer diagnosis, the level of suspicion for a paraneoplastic disorder depends on the symptom duration, neurologic syndrome, tumor histology, and presence of antineuronal antibodies. For example, small-cell lung carcinoma or Hodgkin lymphoma are much more often associated with paraneoplastic disorders than squamous-cell lung carcinoma or non-Hodgkin lymphoma. Tumor metastases and neurotoxicity of cancer treatments are far more common than paraneoplastic disorders and should always be considered, as should metabolic derangements and CNS infection. New advances, such as immune checkpoint inhibitors, can also induce focal limbic or extra limbic encephalitis in patients with cancer. It is important to consider this a potential differential diagnosis for paraneoplastic encephalitis. Rarely, undetected preexisting paraneoplastic encephalitis can also be unmasked by immune checkpoint inhibitors (49).

For patients without a previous cancer diagnosis, the level of suspicion for a paraneoplastic disorder depends on patient age, gender, risk factors (especially cigarette smoking), the neurologic syndrome, and the presence of antineuronal antibodies. Several syndromes should always raise the possibility of a paraneoplastic etiology, including Lambert-Eaton myasthenic syndrome, rapidly progressive cerebellar syndrome, severe sensory neuronopathy, limbic encephalopathy, and opsoclonus-myoclonus (21; 19). A rather short list of possible associated neoplasms exists for each of these syndromes.

No clinical neurologic syndrome is absolutely associated with neoplasia; every neurologic "paraneoplastic syndrome" can occur in patients without a tumor, with the proportion of paraneoplastic versus nonparaneoplastic etiologies varying among individual syndromes. With increasing recognition of patients with autoantibodies such as anti-NMDAR antibodies, anti-GABAB receptor antibodies, and antibodies against the VGKC complex, CNS paraneoplastic disorders can be viewed as a subset of autoimmune encephalitides in adults and children (23; 26; 29).

Diagnostic workup

The most important consideration is the disease course. Patients with paraneoplastic encephalitis often have subacute onset of symptoms, such as focal findings, seizures, cognitive changes, psychiatric symptoms, or autonomic dysfunction over 3 months or less. A more rapid onset over days should raise suspicion for an infectious process, whereas a more gradual onset should raise suspicion for a neurodegenerative etiology. The typical workup for possible paraneoplastic encephalitis often includes brain MRI with and without contrast, EEG, lumbar puncture, and antibody testing.

Brain MRI scans in patients with paraneoplastic encephalomyelitis may (or may not) show focal lesions in the cerebral cortex, limbic system, basal ganglia, brainstem, or spinal cord in patients with corresponding clinical involvement. In the acute phase of rapidly progressive cerebellar syndrome, opsoclonus-myoclonus, or brainstem encephalitis, brain MRI scans are usually normal but may show lesions in the cerebellum or brainstem. Brain MRI scans in most patients with paraneoplastic limbic encephalitis show areas of abnormal T2-weighted or FLAIR signal in the mesial temporal lobe and amygdala bilaterally and, less commonly, in the hypothalamus and basal frontal cortex. Most patients with paraneoplastic myelopathy have abnormal spine MRI scans (17). If present, MRI lesions in patients with CNS paraneoplastic disorders are nonspecific, and one cannot distinguish a paraneoplastic etiology from other conditions.

Most patients with a CNS paraneoplastic syndrome have abnormal cerebrospinal fluid, including some combination of mildly elevated protein, mild mononuclear pleocytosis, elevated IgG index, or oligoclonal bands. Normal cerebrospinal fluid does not exclude a paraneoplastic diagnosis. In addition, when normal initially, one can consider repeating cerebrospinal fluid testing within a week or two, which in some instances may finally show evidence of immunologic response intrathecally. EEG can also help demonstrate epileptic or slow-wave activities. Extreme delta brush on EEG can be seen in anti-NMDAR encephalitis, although this is a late finding in the disease course (43).

One must note that serum and cerebrospinal fluid have different sensitivities for the antibodies of interest, and sending out both serum and cerebrospinal fluid paraneoplastic panel or autoimmune encephalitis panel has become the standard of care.

In a retrospective study of confirmed autoimmune encephalitis cases, FDG-PET CT scan of the brain was shown to be one of the earliest abnormalities detected, even when MRI/EEG/cerebrospinal fluid testing was unremarkable. The most common finding was hypometabolism of various brain regions (41). In this author’s opinion, one must exercise caution and never rely on an abnormal FDG-PET CT scan of the brain as a sole indicator of autoimmune encephalitis or a reason to administer an immunologic agent, as FDG-PET scans are frequently abnormal in patients with other disorders. To date, no specific pattern of FDG-PET scan abnormality is specific for autoimmune encephalitis.

Nerve conduction studies and electromyography are valuable in characterizing the clinical syndrome in patients with suspected peripheral nervous system paraneoplastic disorders (eg, Lambert-Eaton myasthenic syndrome, neuromyotonia, or sensory neuronopathy) but cannot in themselves differentiate a paraneoplastic versus nonparaneoplastic etiology.

The tumor workup for adults should include CT or MRI scans of the chest and abdomen (47). Chest CT or MRI scanning is clearly more sensitive than "plain" chest x-rays in detecting a lung neoplasm. Women should additionally have mammography and examination and imaging of the pelvic organs. Testicular ultrasound in young men may detect a small germ cell tumor or microcalcifications indicative of microscopic intratubular germ cell tumor (34). Exploratory laparoscopy and blind oophorectomy have enabled discovery of small ovarian teratomas in some patients with anti-NMDAR-associated encephalitis (11). Total-body fluorodeoxyglucose positron emission tomography (FGD-PET) with fused CT scanning of the chest and abdomen may demonstrate a neoplasm in patients with suspected paraneoplastic disorders (with or without autoantibodies) in whom other imaging studies are negative or equivocal (24; 36; 35). For patients with any of the syndromes, it is not uncommon for the tumor to be found only after repeated searches. As paraneoplastic syndromes can precede tumor detection by at least several years, when the initial tumor workup is negative, it should be repeated yearly for the first 5 years, though no specific guideline has been established to date.

Good but not perfect correlations exist among individual paraneoplastic syndromes, antineuronal antibody specificities, and associated tumor types (Table 2). The practical clinical value of antineuronal antibodies is that, when present, they greatly increase the index of suspicion for a paraneoplastic condition, and the type of antibody can help guide the search for the associated tumor. Antineuronal antibody assays do, however, have important practical clinical limitations:

	(1) Heterogeneity exists, in that a given clinical syndrome (eg, rapidly progressive cerebellar syndrome) may be associated with one of several autoantibodies.
	(2) Conversely, a given autoantibody (eg, anti-Hu) may be associated with various clinical presentations.
	(3) For most, if not all, neurologic syndromes, some patients have antineuronal autoantibodies and yet never develop a demonstrable tumor. The prime examples are Lambert-Eaton syndrome, neuromyotonia, and limbic encephalitis. Therefore, the presence of antibodies does not absolutely indicate an underlying neoplasm.
	(4) Some autoantibodies are present at low titers in tumor patients without any accompanying clinical neurologic manifestations.
	(5) Patients with a suspected paraneoplastic syndrome may not have demonstrable antineuronal antibodies or may have "atypical" or incompletely characterized antibodies not detected in commercially available assays. Some patients initially determined to be "negative" for the more common antibodies turn out eventually to have newly recognized antibodies as the list of paraneoplastic antibodies grows (31; 12; 29). A negative antibody assay, therefore, does not rule out the possibility of a paraneoplastic disorder and the presence of an underlying neoplasm.

The ever-growing list of antineuronal antibodies associated with paraneoplastic disorders, as well as the heterogeneity of clinical-antibody associations, complicate decision-making for the clinician in deciding "which antibodies to order." Several antibodies have been described in only a small number of patients, and the practical utility of ordering all antibodies in all patients is highly debatable. Many laboratories perform a panel of different antibody assays (depending on the clinical syndrome) or perform a screening with immunohistochemistry or immunoblotting to be followed by specific antibody identification if necessary.

There are various predictive models and diagnostic algorithms for suspected paraneoplastic syndromes. Graus and colleagues proposed categorizing these phenotypes into two groups: “high risk,” which encompasses conditions such as encephalomyelitis, limbic encephalitis, rapidly progressive cerebellar syndrome, opsoclonus-myoclonus, sensory neuronopathy, enteric neuropathy, and Lambert-Eaton myasthenic syndrome; and “intermediate risk,” which includes multifocal or diffuse involvement not confined to the limbic system, brainstem encephalitis, anti NMDAR encephalitis (depends on age and sex), Morvan syndrome, and stiff-person syndrome. Antibodies are also categorized into high-risk antibodies (greater than 70% cancer association), such as Hu, CRMP5, PCA2, SOX1, Amphiphysin,Ri, Yo, Ma, Tr, KLHL11; intermediate-risk antibodies (30% to 70%), such as AMPAR, GABA, mGluR5, P/Q VGCC, NMDAR, CASPR2; and lower-risk antibodies (less than 30% or negative), such as GFAP, GAD65, MOG, AQP4, GlyR, DPPX, LGI1, CASPR2, GABAA R, and mGluR1. The PNS-Care Score then utilizes the type of phenotype, antibody, and presence of cancer to risk-stratify patients into possible, probable, and definite paraneoplastic syndromes.

Management

Management of patients with known or suspected paraneoplastic syndromes includes the following components:

(1) verification that the disorder is, in fact, paraneoplastic;
(2) diagnosis of the associated tumor;
(3) treatment of the tumor;
(4) suppression of the autoimmune effectors causing neuronal injury.

Several neurologic syndromes are considered “high risk” in that they are strongly associated with cancer (22). These include multifocal encephalomyelitis, limbic encephalitis, rapidly progressive cerebellar syndrome, opsoclonus-myoclonus, subacute sensory neuronopathy, chronic gastrointestinal pseudo-obstruction, Lambert-Eaton myasthenic syndrome, and dermatomyositis. Patients presenting with any of these syndromes should be thoroughly investigated for an associated neoplasm, regardless of the presence or absence of onconeural antibodies.

The workup to find an associated tumor should be guided by the known associations between particular clinical syndromes and tumor types and by the type of autoantibodies, if present.

When the tumor is definitely diagnosed, it should be treated with the appropriate surgical, chemotherapeutic, or radiation measures. For at least some patients with CNS paraneoplastic disorders, successful tumor treatment is associated with better neurologic outcomes (48). There is low-level evidence in a systemic review that the rate of relapse in patients with NMDAR antibody encephalitis is lower in patients who had resection of ovarian teratoma (16). Patients with some syndromes, most notably limbic encephalitis and opsoclonus-myoclonus in adults or children, often show neurologic improvement solely with successful tumor therapy. Some patients with rapidly progressive cerebellar syndrome and Hodgkin lymphoma, and exceptional patients with carcinoma, improve neurologically after successful tumor treatment. Some patients with peripheral nervous system paraneoplastic disorders also show neurologic improvement with successful tumor treatment. This includes Lambert-Eaton syndrome, neuromyotonia, and probably vasculitis neuropathy and polymyositis as well.

If paraneoplastic disorders are truly autoimmune diseases, they should theoretically respond to immunosuppressive or immunomodulatory treatment. Several factors make it difficult to interpret the published literature regarding immunotherapy for paraneoplastic disorders:

	• These syndromes are relatively rare.
	• Most reports are anecdotal, and nearly all published series are retrospective.
	• A reporting bias exists, in that patients who respond to treatment are more likely to be published than those who do not respond.
	• For some syndromes, pharmacologic treatments can improve neurologic symptoms independent of tumor treatment or immunotherapy; examples include Lambert-Eaton syndrome (pyridostigmine, 3,4-diaminopyridine, or guanidine), limbic encephalitis (psychoactive and antiepileptic drugs), neuromyotonia (phenytoin and carbamazepine), stiff-person syndrome (diazepam and baclofen), and opsoclonus-myoclonus (clonazepam or valproate).
	• Paraneoplastic rapidly progressive cerebellar syndrome, sensory neuronopathy or encephalomyelitis, and other syndromes often stabilize spontaneously (although at a level of severe disability) so that it is difficult to interpret reports of "disease stabilization" with immunotherapy.
	• Perhaps the greatest difficulty in evaluating immunotherapy for paraneoplastic disorders is the confounding effect of tumor treatment. When patients receive concomitant tumor treatment and immunotherapy, it becomes difficult to discern the impact of each therapy on the neurologic outcome. For many syndromes, increasing evidence shows that immunotherapy is more likely to be effective when the tumor is also treated successfully.

Factors that interact in influencing the response to immunotherapy include the neuroanatomic site (central vs. peripheral), the cellular location of the onconeural target antigens (neuronal cell surface vs. intracellular), and the proven or presumed mechanisms of neuronal injury (antibody-mediated vs. cell-mediated). In general, syndromes affecting the peripheral nervous system are more likely to improve with tumor or immunosuppressive treatment than are CNS syndromes. Syndromes caused by autoantibodies reacting with neuronal cell surface receptors or ion channels are more likely to respond to immunotherapy, probably because the antibodies do not usually cause axonal degeneration or neuronal cell death. Prime examples of this are the Lambert-Eaton myasthenic syndrome and neuromyotonia. Patients with encephalitis associated with anti-NMDAR antibodies, anti-GABABR antibodies, or antibodies against the voltage-gated potassium channel complex (anti LGI1 or anti-Caspr2) generally have a good neurologic outcome after immunotherapy (31; 26; 12; 29). Sensory neuronopathy and autonomic insufficiency involve the peripheral nervous system, but patients generally do not respond to therapy, which is probably because neuronal cell bodies in the dorsal root ganglia and autonomic ganglia are irreversibly injured or killed by the autoimmune response.

The decision whether to try immunosuppressive therapies must be based on the particular syndrome and on the individual patient's circumstances. Corticosteroids or IVIG are the most commonly used immunotherapies for paraneoplastic disorders. Patients generally receive an initially high dose of intravenous or oral steroid (prednisone, methylprednisolone, dexamethasone) followed by a slow, cautious taper. No clear evidence indicates the optimal drug, dose, route of administration, or schedule of corticosteroids. IVIG may be tried alone or in combination with corticosteroids. Plasma exchange could arguably be reserved for syndromes that are definitely antibody-mediated, but reports have been made of improvement in patients with other syndromes as well (50).

Some paraneoplastic disorders may respond better to repeated plasma exchanges, whereas others may have a better record at responding to IVIG. In addition, when the antibody specificity is not yet available, many clinicians will choose to proceed with five plasma exchange sessions approximately every other day for a rapid antibody removal and then administer intravenous immunoglobulins for a more extended immune modulation. A system review suggested that steroids or steroids in combination with plasma exchanges improved vision in patients with cancer-associated retinopathy (06).

Rituximab and cyclophosphamide have been used as second-line therapy for adult patients with multifocal or limbic encephalitis who do not respond well to corticosteroids, IVIg, or plasma exchange (31). Cyclophosphamide is often chosen for T-cell-mediated paraneoplastic neurologic syndromes. Chronic oral or pulsed intravenous cyclophosphamide has also been used for various paraneoplastic disorders, with no definite evidence establishing an optimal schedule or dose. Azathioprine or cyclosporine has been used with benefit in some patients with Lambert-Eaton syndrome, with little published information regarding their efficacy in other paraneoplastic disorders. The monoclonal antibody rituximab, which depletes B lymphocytes, produced neurologic improvement in children with neuroblastoma and opsoclonus-myoclonus and in young people with anti-NMDAR encephalitis (40; 09). There are studies of tacrolimus plus prednisone or of sirolimus, which are agents that specifically inhibit activated T-lymphocytes in patients with anti-Hu or anti-Yo-associated syndromes (39; 14). Alternative therapies, such as tocilizumab (an antibody against IL6-R) and bortezomib (a proteosome inhibitor), have been used in refractory cases (07). A phase-2B randomized double-blind placebo-controlled clinical trial is enrolling patients to evaluate the safety and efficacy of inebilizumab, a humanized anti-CD19 monoclonal antibody, in anti-NMDA receptor encephalitis (52).

In the era of immune checkpoint inhibitors, which have transformed oncology management of multiple malignancies, special considerations should be given to checkpoint inhibitor-associated paraneoplastic neurologic syndromes. Checkpoint inhibitors are associated with neurologic immune-related adverse effects, which can manifest as paraneoplastic neurologic syndromes (20). Although rare, occurring in fewer than 1% of patients receiving checkpoint inhibitors, neurologic immune-related adverse effects can present significant diagnostic challenges. In patients who develop paraneoplastic neurologic syndromes after starting checkpoint inhibitors, this can manifest as myasthenia gravis, limbic encephalitis, cerebellar ataxia, aseptic meningitis, or peripheral neuropathies. However, it is also important to rule out CNS progression of cancer and other alternative neurologic conditions. Symptoms may mimic classical paraneoplastic neurologic syndrome and often begin within 3 months of starting checkpoint inhibitors, although onset can be delayed. Onconeuronal autoantibodies can be detected in these patients. Checkpoint inhibitors should be discontinued, and corticosteroids are often prescribed. Similar to classical paraneoplastic neurologic syndromes, checkpoint inhibitor-induced paraneoplastic syndromes associated with antibodies against surface neuronal antigens respond better than those against intracellular antigens. IVIG and plasma exchange as well as rituximab and other immunosuppressants, such as cyclophosphamide and natalizumab, have been explored as second-line options. The decision to rechallenge with checkpoint inhibitors is highly individualized, but the ASCO clinical practice guideline recommends against rechallenge checkpoint inhibitors in patients who experienced severe neurologic immune-related adverse effects (05).

Outcomes

Prognosis after treatment is typically most favorable in paraneoplastic CNS syndromes with antibodies directed against cell surface antigens. The most extensive observational cohort study on anti-NMDAR encephalitis, which included 577 patients, revealed that 81% of patients experienced a favorable outcome after 24 months (46). For some patients, the recovery process took as long as 18 months. Additionally, the study identified a 12% risk of relapse within a 2-year period, with most relapses being less severe than the initial episode.

Unfortunately, the two most prevalent paraneoplastic CNS syndromes in adults, ie, encephalomyelitis or sensory neuronopathy associated with anti-Hu antibodies and cerebellar degeneration associated with anti-Yo antibodies, usually have a poor neurologic prognosis despite aggressive tumor treatment and a variety of immunosuppressive therapies (48). Patients with other CNS syndromes, including opsoclonus-myoclonus, limbic encephalitis, and stiff-person syndrome, have a somewhat higher likelihood of neurologic improvement, suggesting that the immune-mediated neuronal dysfunction or injury is less severe or of a sort more likely to be reversible. A few patients show a meaningful neurologic response to immunotherapy, even for the "unfavorable" syndromes, such as encephalomyelitis and rapidly progressive cerebellar syndrome. For these few responders, the only factors that sometimes correlate with neurologic improvement are successful tumor treatment and the duration and severity of neurologic deficits before diagnosis and initiation of therapy. For patients who have already stabilized at a plateau of severe neurologic disability for more than several weeks, subsequent improvement with any intervention is not impossible but extremely unlikely.

Several potential explanations exist for the disappointingly poor response to immunotherapy in many patients. The continuing presence of even a small tumor burden seems to provide an "antigenic drive" for further neuronal injury. It is also likely that current immunotherapies do not adequately gain access to the central nervous system and do not effectively abrogate an ongoing autoimmune response that is "sequestered" in the central nervous system. Unfortunately, for many central syndromes, patients likely have already suffered neuronal death or irreversible injury by the time a paraneoplastic disorder is diagnosed.

Theoretical concern exists that if paraneoplastic disorders arise from an immune response directed against the tumor, attempts to treat the neurologic disorder with immunosuppression may adversely affect the evolution of the tumor. At this time, no definite evidence shows that patients given immunosuppressive treatment have a worse tumor outcome.

Special considerations

Pregnancy

When a paraneoplastic disorder arises during pregnancy, the search for a tumor, tumor removal, and adequate immunologic therapy are vital for maternal-fetal outcomes. The side effects of diagnostic imaging (for example, CT chest/abdomen/pelvis) must be weighed against the risks associated with the lack of a timely diagnosis and treatment.

Most pregnant women can safely undergo cerebrospinal fluid testing and can have MRI/ultrasound modalities employed as an initial strategy for tumor detection.

Immunologic therapies such as intravenous steroids and intravenous immunoglobulins can generally be safely administered in pregnant women (with specific trimester precautions) when the benefits clearly outweigh the risks. This decision should always be discussed with an obstetrician in charge of the patient’s care.

In patients not responding to the first-line treatment who are rapidly deteriorating (for example, seizing), a second-line therapy such as rituximab should be instituted. A limited amount of literature and experience suggests that rituximab can be safely administered to pregnant women in life-threatening situations and in disorders that carry a high risk of morbidity and mortality to the mother and fetus if not treated promptly. In the world of neuroimmunology, patients with neuromyelitis optica frequently receive rituximab during pregnancy. A retrospective study, though based on a small sample size (102), showed no increased risk of spontaneous abortion or an increased risk of fetal malformation in babies exposed to rituximab in utero (13). Long-term effects of in utero exposure to rituximab have never been studied in an organized fashion. A case series demonstrated that patients often experience obstetric complications, but newborns had normal development despite immunotherapy use during pregnancy in 64% of cases (30).

Anesthesia

Patients with Lambert-Eaton myasthenic syndrome may develop severe, prolonged weakness, respiratory insufficiency, or both with neuromuscular blocking agents.

References

01: Armangue T, Titulaer MJ, Málaga I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013;162(4):850-6.e2. PMID 23164315
02: Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012;135(Pt 5):1622-38. PMID 22539258
03: Binks S, Uy C, Honnorat J, Irani SR. Paraneoplastic neurological syndromes: a practical approach to diagnosis and management. Pract Neurol 2022;22(1):19-31. PMID 34510016
04: Brain WR, Wilkinson ML. Subacute cerebellar degeneration associated with neoplasms. Brain 1965;88:465-78. PMID 5890520
05: Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36(17):1714-68. PMID 29442540
06: Brossard-Barbosa N, Dezard V, Margolin E. Treatment of cancer-associated retinopathy: a systematic literature review. Ophthalmol Retina 2023;7(9):819-28. PMID 37160190
07: Ciano-Petersen NL, Muñiz-Castrillo S, Vogrig A, Joubert B, Honnorat J. Immunomodulation in the acute phase of autoimmune encephalitis. Rev Neurol (Paris) 2022;178(1-2):34-47. PMID 35000790
08: Corsellis JA, Goldberg GJ, Norton AR. "Limbic encephalitis" and its association with carcinoma. Brain 1968;91(3):481-96. PMID 5723018
09: Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS diseases. Neurology 2014;83(2):142-150. PMID 24920861
10: Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev 2017;97(2):839-87. PMID 28298428
11: Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63-74. PMID 21163445
12: Dalmau J, Rosenfeld MR. Autoimmune encephalitis update. Neuro Oncol 2014;16(6):771-8. PMID 24637228
13: Das G, Damotte V, Gelfand JM, et al. Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm 2018;5(3):e453. PMID 29564373
14: de Jongste AH, van Gelder T, Bromberg JE, et al. A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndrome. Neuro Oncol 2015;17(1):145-50. PMID 24994790
15: Eaton LM, Lambert EH. Electromyography and electrical stimulation of nerves in diseases of the motor unit: observations on a myasthenic syndrome associated with malignant tumors. JAMA 1957;163:1117-24. PMID 13405774
16: Erlebach R, Brandi G. Effect and timing of operative treatment for teratoma associated N-Methyl-d-Aspartate receptor-antibody encephalitis: a systematic review with meta-analysis. J Neuroimmunol 2023;382:578153. PMID 37499300
17: Flanagan EP, McKeon A, Lennon VA, et al. Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology 2011;76(24):2089-95. PMID 21670438
18: Geis C, Weishaupt A, Hallermann S, et al. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 2010;133:3166-80. PMID 20884644
19: Giometto B, Grisold W, Vitaliani R, et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database. Arch Neurol 2010;67:330-5. PMID 20212230
20: Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 2019;16(9):535-48. PMID 30867573
21: Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135-40. PMID 15258215
22: Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 2021;8(4):e1014. PMID 34006622
23: Hacohen Y, Wright S, Waters P, et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatr 2013;84(7):748-55. PMID 23175854
24: Hadjivassiliou M, Alder SJ, Van Beek EJ, et al. PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit. Acta Neurol Scand 2009;119(3):186-193. PMID 18855873
25: Henson RA, Hoffman HL, Urich H. Encephalomyelitis with carcinoma. Brain 1965;88:449-64. PMID 5890519
26: Hoftberger R, Titulaer MJ, Sabater L, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013;81(17):1500-6. PMID 24068784
27: Horta ES, Lennon VA, Lachance DH, et al. Neural autoantibody clusters aid diagnosis of cancer. Clin Cancer Res 2014;20(14):3862-9. PMID 24833664
28: Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010;133:2734-2748. PMID 20663977
29: Irani SR, Gelfand JM, Al-Diwani A, Vincent A. Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol 2014;76(2):168-84. PMID 24930434
30: Joubert B, García-Serra A, Planagumà J, et al. Pregnancy outcomes in anti-NMDA receptor encephalitis: case series. Neurol Neuroimmunol Neuroinflamm 2020;7(3):e668. PMID 31948997
31: Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011a;77:179-89. PMID 21747075
32: Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamate receptor 5 in Ophelia syndrome. Neurology 2011b;77(18):1698-701. PMID 22013185
33: Martin-Garcia E, Mannara F, Gutierrez J, et al. Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice. J Neuroimmunol 2013;261(1-2):53-9. PMID 23726906
34: Mathew RM, Vandenberghe R, Garcia-Merino A, et al. Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. Neurology 2007;68(12):900-5. PMID 17151337
35: Matsuhisa A, Toriihara A, Kubota K, Makino T, Mizusawa H, Shibuya H. Utility of F-18 FDG PET/CT in screening for paraneoplastic neurological syndromes. Clin Nucl Med 2012;37(1):39-43. PMID 22157026
36: McKeon A, Apiwattanakul M, Lachance DH, et al. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders. Arch Neurol 2010;67:322-9. PMID 20065123
37: McKeon A, Pittock SJ. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol 2011;122(4):381-400. PMID 21938556
38: Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ. Acute mechanisms underlying antibody effects in anti-NMDA receptor encephalitis. Ann Neurol 2014;76(1):108-19. PMID 24916964
39: Orange D, Frank M, Tian S, et al. Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens. Arch Neurol 2012;69(9):1132-40. PMID 22566506
40: Pranzatelli MR, Tate ED, Swan JA, et al. B cell depletion therapy for new-onset opsoclonus-myoclonus. Mov Disord 2010;25:238-42. PMID 20063398
41: Probasco JC, Solnes L, Nalluri A, et al. Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm 2017;4(4):e352. PMID 28567435
42: Scarlato M, Previtali SC, Carpo M, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain 2005;128:1911-20. PMID 15975949
43: Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012;79(11):1094-100. PMID 22933737
44: Seute T, Leffers P, ten Velde G, Twijnstra A. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer 2004;100:801-6. PMID 14770437
45: Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology 2000;54:2176-8. PMID 10851390
46: Titulaer MJ, McCracken L, Gabilondo I,et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12(2):157-65. PMID 23290630
47: Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumors in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011;18(1):19-e3. PMID 20880069
48: Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS task force. Eur J Neurol 2006;13(7):682-90. PMID 16834698
49: Velasco R, Villagrán M, Jové M, et al. Encephalitis induced by immune checkpoint inhibitors: a systematic review. JAMA Neurol 2021;78(7):864-73. PMID 33720308
50: Vernino S, O'Neill BP, Marks RS, O’Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neurooncol 2004;6:55-62. PMID 14769141
51: Vogrig A, Muñiz-Castrillo S, Desestret V, Joubert B, Honnorat J. Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors. Ther Adv Neurol Disord 2020;13:1756286420932797. PMID 32636932
52: Wong KH, Day G, Torner J, et al. The extinguish trial: A phase-2B randomized placebo-controlled trial of inebilizumab in anti-NMDA receptor encephalitis. J Neurol Sci 2022;99:S39-40.

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Nicholas Butowski MD

Dr. Butowski of the University of California, San Francisco, has no relevant financial relationships to disclose.
See Profile
Anh Huan Vo MD

Dr. Huan Vo of the University of California, San Francisco has no relevant financial relationships to disclose.
See Profile

Editor

Rimas V Lukas MD

Dr. Lukas of Northwestern University Feinberg School of Medicine received honorariums from Novartis and Novocure for speaking engagements, honorariums from Cardinal Health, Novocure, and Merck for advisory board membership, and research support from BMS as principal investigator.
See Profile

Former Authors

Edward J Dropcho MD
Elena Grebenciucova MD

Patient Profile

Age range of presentation: 1 month to 65+ years
Sex preponderance: female>male, 1:1
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Eaton-Lambert syndrome: G73.1

Malignant neoplasm of central nervous system, unspecified: C72.0

Paraneoplastic limbic encephalopathy: G13.1

Paraneoplastic neuromyopathy and neuropathy: G13.0
ICD-11: Lambert-Eaton syndrome: 8C62

Unspecified malignant neoplasms of unspecified sites: 2D4Z

Paraneoplastic or autoimmune disorders of the peripheral or autonomic nervous system: 8E4A.1

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Paraneoplastic syndromes

Associated Disorders

Autonomic insufficiency
Brainstem encephalitis
Cerebellar degeneration
Extrapyramidal syndrome
Hodgkin lymphoma
- Lambert-Eaton myasthenic syndrome
- Limbic encephalitis
- Motor neuron disease
- Motor neuropathy
- Multifocal encephalomyelitis
- Myasthenia gravis
- Myelopathy
- Necrotizing myopathy
- Nerve vasculitis
- Neuromyotonia
- Opsoclonus-myoclonus
- Optic neuritis
- Polymyositis/dermatomyositis
- Retinal degeneration
- Sensorimotor polyneuropathy
- Sensory neuronopathy
- Stiff person syndrome

Differential Diagnosis

squamous cell lung carcinoma
non-Hodgkin lymphoma

Also Relevant

Autosomal dominant hereditary ataxias
Lambert-Eaton myasthenic syndrome
Nerve plexus metastases
Nondominant hereditary ataxias
Paraneoplastic cerebellar degeneration
- Paraneoplastic limbic encephalitis
- Paraneoplastic opsoclonus myoclonus syndrome in adults
- Paraneoplastic retinopathy
- Paraneoplastic sensory neuronopathy
- Stiff-person syndrome

Paraneoplastic syndromes

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Neurologic Paraneoplastic Disorders

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 2. Paraneoplastic Disorders and Autoantibodies

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Autoantibodies: mechanism and testing

NF2-related schwannomatosis

Tumors of the skull base

Multiple sclerosis: treatment of its symptoms

Anti-GQ1b antibody syndrome

Ganglioglioma

Overview of neuropathology updates for infiltrating gliomas

Anti-IgLON5 disease

This is an article preview.
Start a Free Account
to access the full version.